This is coherent with the results of a phase III study conducted by Scagliotti et al., which also compared erlotinib plus tivantinib to erlotinib plus placebo in 109 EGFR mutated NSCLC patients with varying MET mutational statuses. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.